Acute respiratory distress syndrome: epidemiology and management approaches

Allan J Walkey 1
Ross Summer 1
Vu Ho 1
Philip Alkana 2

1The Pulmonary Center, Boston University School of Medicine, Boston, MA, USA; 2Asthma Research Center, Brigham and Women’s Hospital, Boston, MA, USA

Abstract: Acute lung injury and the more severe acute respiratory distress syndrome represent a spectrum of lung disease characterized by the sudden onset of inflammatory pulmonary edema secondary to myriad local or systemic insults. The present article provides a review of current evidence in the epidemiology and treatment of acute lung injury and acute respiratory distress syndrome, with a focus on significant knowledge gaps that may be addressed through epidemiologic methods.

Keywords: acute lung injury, acute respiratory distress syndrome, review, epidemiology

Introduction

The terms “acute lung injury” (ALI) and “acute respiratory distress syndrome” (ARDS) describe syndromes of acute onset, bilateral, inflammatory pulmonary infiltrates and impaired oxygenation. The first known description of ARDS arrived with the invention of the stethoscope; Laennec described fatal “idiopathic pulmonary edema” in his Treatise on Diseases of the Chest, published in 1821. The wars of the twentieth century provided ample evidence that a myriad of traumatic insults could result in edematous lung injury, 1,2 and various terms (eg, “wet lung,” “shock lung,” “Da Nang lung”) were developed to describe these conditions. However, it was not until 1967 that Ashbaugh et al introduced the term “respiratory distress syndrome” to describe the constellation of acute onset tachypnea, hypoxemia, diffuse pulmonary infiltrates, and loss of lung compliance characterized by high short-term mortality in adults. 3

The terms ALI and ARDS finally achieved a consensus definition during the American–European Consensus Conference (AECC) on ARDS (Table 1) in 1994, 4 an accomplishment that allowed coordinated research efforts (eg, initiation of the National Heart, Lung, and Blood Institute’s Acute Respiratory Distress Syndrome Network [ARDSNet]) into the epidemiology, pathophysiology, and treatment of ALI/ARDS. In this review, we will discuss the current understanding of pathophysiology, epidemiology, and evidence-based therapeutic approaches for ALI and ARDS.

Definition

Although the AECC definitions allowed for a concerted ALI/ARDS research effort, the validity of the definition has been criticized. For example, the vague nature of the term “acute,” wide intraobserver variation in ascertaining “bilateral radiographic infiltrates,” 5 and sensitivity of the PaO 2 /FiO 2 ratio criteria to small changes in positive end-expiratory pressure (PEEP) 6 led to the recent revisiting of the AECC definition.
and drafting of the Berlin definition of ARDS\(^7\) (Table 1). The Berlin criteria were unique in that they were iteratively drafted and then empirically evaluated in order to provide a definition that would be feasible, reliable, and prognostic. Major changes to the AECC definition included: (1) elimination of the term “acute lung injury” as the umbrella term and replacing it with three levels of ARDS severity based on PaO\(_2\)/FiO\(_2\) measured with at least 5 cm H\(_2\)O of applied PEEP; (2) defining “acute” as ≤7 days from the predisposing clinical insult, and (3) eliminating pulmonary wedge pressure cutoff values that discriminate ARDS from cardiogenic edema. The Berlin criteria provide a slight improvement in predictive ability for mortality (area under the curve [AUC] 0.577) when compared to the AECC (0.536). In the following review, we will use the Berlin terminology when referring to different subdivisions of PaO\(_2\)/FiO\(_2\) severity, where applicable.

**Pathophysiology**

The pathology of ARDS may progress through three overlapping stages: exudative, proliferative, and fibrotic.\(^5,9\) Direct or indirect lung insults (Table 2) initiate the exudative phase. This phase is the acute inflammatory stage of ARDS, typified by release of proinflammatory cytokines, influx of neutrophils, and impaired endothelial cell barrier function. Respiratory failure during the exudative phase is attributed to accumulation of protein-rich fluid in distal airspaces and to decreased surfactant production by type II epithelial cells. These early events are followed by the proliferative phase, which develops 2–7 days after initiation of lung injury. This phase is characterized by the proliferation of type 2 pneumocytes, early fibrotic changes, and myointimal thickening of the alveolar capillaries.\(^8,10\) In some individuals, the proliferative phase progresses to a fibrotic stage that is associated with increased collagen deposition, a prolonged period of ventilation–perfusion mismatching, and diminished compliance of the lung. As evident, the clinical syndrome of ARDS results in multiple pathophysiological changes causing severe respiratory dysfunction.

**Epidemiology**

**Prevalence and incidence**

Cross-sectional studies demonstrate that patients with ARDS represent approximately 5% of hospitalized, mechanically ventilated patients.\(^11\) Most studies have shown that rates of mild ARDS (PaO\(_2\)/FiO\(_2\) 200–300) represent only 25% of patients with ARDS, with approximately 75% of patients having moderate or severe ARDS.\(^7,12\) However, approximately one-third of patients with initially mild ARDS will later progress to moderate or severe disease; identification of factors associated with progression of mild ARDS requires further study. The incidence of ARDS varies widely. For example, estimates from prospective US cohort studies using the AECC definition range from 64.2\(^13\) to 78.9\(^12\) cases/100,000 person-years, whereas estimates from Northern Europe (17 cases/100,000),\(^14\) Spain (7.2 cases/100,000),\(^13\) and Australia/New Zealand (34 cases/100,000)\(^16\) have shown substantially lower rates. Rea-

### Table 1

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>The AECC definition 1994</th>
<th>The Berlin definition 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Acute</td>
<td>≤7 days from the predisposing clinical insult</td>
</tr>
<tr>
<td>Radiographic abnormality</td>
<td>Bilateral infiltrate on frontal chest radiograph</td>
<td>Bilateral opacities on radiograph or computed tomography scan not fully explained by effusion, atelectasis, or nodule</td>
</tr>
<tr>
<td>Noncardiogenic source of pulmonary edema</td>
<td>No clinical evidence of elevated left atrial pressure, or, a pulmonary capillary wedge pressure &lt; 18 mmHg</td>
<td>Respiratory failure not fully explained by cardiogenic pulmonary edema or volume overload</td>
</tr>
<tr>
<td>Oxygenation</td>
<td>PaO(_2)/FiO(_2) ratio</td>
<td>PaO(_2)/FiO(_2) ratio with ≥5 cm H(_2)O positive end-expiratory pressure (PEEP)</td>
</tr>
<tr>
<td></td>
<td>Acute lung injury: ≤300</td>
<td>Mild ARDS: 201–300</td>
</tr>
<tr>
<td></td>
<td>Acute respiratory distress syndrome: ≤200</td>
<td>Moderate ARDS: 101–200</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe ARDS: &lt;100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If none identified, then need to rule out cardiogenic edema with additional data (eg, echocardiography)</td>
</tr>
<tr>
<td>Predisposing condition</td>
<td>Not specified</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Direct lung injury</th>
<th>Indirect lung injury</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>Severe sepsis</td>
</tr>
<tr>
<td>Aspiration of gastric contents</td>
<td>Blood transfusion</td>
</tr>
<tr>
<td>Lung contusion</td>
<td>Trauma</td>
</tr>
<tr>
<td>Toxic inhalation</td>
<td>Cardiopulmonary bypass</td>
</tr>
<tr>
<td>Near-drowning</td>
<td>Pancreatitis</td>
</tr>
</tbody>
</table>

Dovepress
Clinical Epidemiology 2012:4
sons for the large variation in ARDS incidence are unclear, and may include major differences in demographics and healthcare delivery systems. The challenges of recognizing ARDS in administrative data—which requires identification by the clinician, notation in the chart, and subsequent coding by an administrator—have limited the evaluation of temporal trends and ARDS incidence over larger population-based samples. Improving the accuracy of ARDS recognition in administrative data represents fertile opportunity for further study.

Risk factors
A number of single-center prospective cohort studies that enrolled patients at risk for ARDS have identified risk factors for the development of ARDS. Nonmodifiable risk factors for ARDS include a history of alcohol abuse (odds ratio [OR] 2.8), obesity (OR 1.2 per standard deviation increase in body mass index), and admission severity of illness (OR 2.1 for Acute Physiology and Chronic Health Evaluation [APACHE] II > 16). Prospective studies have shown either no association or a protective association between older age and ARDS development. Potentially modifiable risk factors for ARDS include increased use of red blood cell transfusion (OR 1.5 per unit), admission hypoproteinemia (OR 2.8 for each decline of 2 g/dL of admission total protein), failure to achieve resuscitation goals within 6 hours of septic shock onset (OR 3.5), and failure to provide adequate antibiotics within 3 hours of septic shock (OR 2.4). Interestingly, patients with diabetes have approximately half the risk for developing ARDS as at-risk patients without diabetes. Determining mechanisms for these risk factors may allow for the development of therapies that prevent ARDS.

Gajic et al have consolidated prior ARDS risk-factor data in order to develop and validate an acute lung injury prediction score (LIPS). The multicenter LIPS study prospectively observed 5992 patients admitted with a predisposing condition for ARDS (shock, sepsis, pneumonia, pancreatitis, high-risk trauma, or high-risk surgery). Approximately 10% of at-risk patients developed ARDS, though incidence varied greatly with predisposing condition (from 2.7% of patients with pancreatitis to 27% of patients with smoke inhalation). Table 3 demonstrates factors associated with development of ARDS in the LIPS multivariable-adjusted model. The optimal LIPS score cutoff (AUC 0.8) predicted ARDS with only fair sensitivity (69%) and specificity (78%), demonstrating the difficulty of predicting ARDS in at-risk patients.

### Table 3 Multivariable-adjusted predisposing conditions and clinical risk factors for acute lung injury (Lung Injury Prediction Study)²⁸

<table>
<thead>
<tr>
<th>Predisposing conditions</th>
<th>Proportion of patients with condition who develop ARDS</th>
<th>Odds ratio for developing ARDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity (body mass index &gt; 30)</td>
<td>1.75</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes (only in sepsis; associated with decreased risk)</td>
<td>0.55</td>
<td>-</td>
</tr>
<tr>
<td>Hypoalbuminemia</td>
<td>1.58</td>
<td>-</td>
</tr>
<tr>
<td>FiO₂ &gt; 0.35</td>
<td>2.77</td>
<td>-</td>
</tr>
<tr>
<td>pH &lt; 7.35</td>
<td>1.73</td>
<td>-</td>
</tr>
<tr>
<td>Tachypnea (respiratory rate &gt; 30)</td>
<td>1.99</td>
<td>-</td>
</tr>
</tbody>
</table>

**Abbreviation:** ARDS, acute respiratory distress syndrome.

Mortality
ARDS is associated with a hospital mortality of approximately 40%. Mortality varies according to severity of oxygenation deficit. In the Berlin definition clinical study cohort, mortality was 27% (95% confidence interval [CI] 24%–30%) in patients with mild ARDS (PaO₂/FiO₂ 201–300), 32% (95% CI 29%–34%) in those with moderate ARDS (PaO₂/FiO₂ 101–200), and 45% (95% CI 42%–48%) in patients with severe ARDS. Although worsening oxygenation is a risk factor for ARDS mortality, patients generally die from multisystem organ failure or progressive underlying illness; only a minority of ARDS patients (13%–19%) die from refractory respiratory failure. Although mortality has declined since two decades ago, initial progress in reducing ARDS mortality is likely due to increased implementation of a low tidal–volume mechanical ventilation strategy that reduces further lung injury, systemic inflammation, and subsequent multisystem organ failure. However, among patients who receive low tidal–volume ventilation, mortality rates remain unchanged. Thus, additional treatments for ARDS are sorely needed.

Because of the high mortality and substantial variability in outcomes in patients with ARDS, identification of risk factors for mortality is important to determine prognosis and guide clinical decision-making. In line with observations that mortality in ARDS is generally due to multiple-organ system failure, the best-performing deter-
minants of prognosis in ARDS are age, severity of disease indices (eg, APACHE scores), and predisposing conditions for ARDS. For example, trauma-induced ARDS has a much more favorable prognosis (approximately 10% mortality) than other conditions. Clinical risk factors for ARDS mortality include poor oxygenation and poor lung compliance, although the Berlin ARDS Definition Task Force did not find that lung compliance added significant predictive value over oxygenation alone. Other predictors of ARDS mortality include pulmonary vascular dysfunction, lack of temporal improvement in dead-space fraction, lung compliance, oxygenation, or shock.

Life after ARDS
Given the severity of lung-tissue destruction in patients with ARDS, clinicians generally accepted that severe, long-term pulmonary insufficiency was an inevitable outcome for survivors of ARDS. Recent epidemiological studies suggest this is not true. In fact, these studies indicate that lung function in survivors approaches prebaseline levels in the majority of patients within 1 year. However, ARDS does exact a significant long-term toll on survivors. For example, many patients with ARDS develop long-term neuromuscular, cognitive, and psychological symptoms. Moreover, survivors utilize increased health services after hospital discharge; ARDS has been shown to be one of the most common reasons for admission to a long-term ventilator rehabilitation unit.

Diagnosis
The diagnosis of ARDS is often clinically challenging because of nonspecific features of this condition. Highlighting the difficulty of ARDS diagnosis, Ferguson et al identified that only 48% of patients with autopsy-proven ARDS had a diagnosis of ARDS noted in their charts. ARDS mimics include cardiogenic pulmonary edema, acute eosinophilic pneumonia, acute interstitial pneumonitis, cryptogenic organizing pneumonia, and diffuse alveolar hemorrhage. To differentiate these conditions from ARDS, various diagnostic modalities are utilized, such as sophisticated chest-imaging studies, echocardiography, right-heart catheterization, and bronchoscopy. Lung biopsy has been reported to change management in 60%–80% of select cases in which the diagnosis of ARDS remains uncertain, though whether outcomes are improved through biopsy-triggered management change is less clear. Importantly, lung biopsy is reserved for a minority of patients in experienced centers because of its high rate of severe complications (10%) in critically ill patients.

Therapeutic strategies
Therapeutic strategies for ARDS focus upon treating the underlying etiology and providing supportive care that reduces the progression of lung injury. Our algorithm for an evidenced-based approach to ARDS is shown in Figure 1.

Mechanical ventilation
Most patients with ARDS develop respiratory failure severe enough to require mechanical ventilatory support. Although often a life-saving intervention, respiratory support with a mechanical ventilator is a double-edged sword that can also exacerbate lung injury. Because ARDS is not a homogeneous process, a disproportional amount of tidal volume during mechanical ventilation is delivered to more compliant, less injured regions (the so-called baby lung), causing overstretch injury to previously functional lung. In addition, mechanical breaths can cause cyclic lung recruitment and collapse, leading to increased shear-stress forces on the gas-exchange units of the lung. The combined mechanistic forces of overdistension and cyclic recruitment cause ventilator-associated lung injury (VALI), which then produces “biotrauma” from systemic release of inflammatory cytokines. Currently, the primary goal for management of ARDS is the reduction of VALI.

Low tidal–volume ventilation
Preclinical animal studies suggested that using low-tidal volumes to ventilate injured lungs minimized lung injury. However, the benefit of this approach was not clearly shown until the first ARDSNet trial (“ARMA”) compared a low tidal–volume (goal 6 mL/kg of ideal body weight) and low plateau–pressure (<30 cm H₂O) strategy to a “conventional” tidal–volume and plateau–pressure (12 mL/kg per ideal body weight, <50 cm H₂O) strategy in 861 ARDS patients. Patients randomized to low tidal volumes/plateau pressures experienced lower 28-day mortality (31.0% versus 38.8%; P = 0.007). In conjunction with these findings, patients receiving low lung volumes had lower plasma levels of the proinflammatory cytokine interleukin 6 and subsequently developed fewer organ failures. These findings suggested the benefits of low tidal–volume ventilation may relate to its ability to minimize both local and distant tissue injury. In conjunction with additional trials investigating lung-protective mechanical ventilation strategies
l lung-protective ventilation using low tidal volumes is now the standard of care in treating patients with ARDS. Details of the ARDSNet low tidal–volume strategy can be found at the ardsnet.org website.

Positive end-expiratory pressure

Another strategy for reducing injury during mechanical ventilation is application of PEEP, which is used to reduce lung collapse at end expiration and improve oxygenation. Like mechanical ventilation itself, PEEP is also a “double-edged sword” that may overdistend and injure more functional lung, leading to increased barotrauma and hemodynamic compromise. The double-edged sword of high PEEP was highlighted in a meta-analysis of three multicenter trials investigating high PEEP (average 15 ± 3 cm H\textsubscript{2}O) versus low PEEP (average 9 ± 3 cm H\textsubscript{2}O) strategies. In a predefined subgroup analysis, the authors demonstrated reduced mortality in patients with moderate–severe ARDS (Pa\textsubscript{O\textsubscript{2}}/Fi\textsubscript{O\textsubscript{2}} < 200) who received high PEEP strategies (34.1% versus 39.1%; relative risk [RR] 0.90 [95% CI, 0.81–1.00], P = 0.049) and a trend towards increased hospital mortality in patients with mild ARDS (Pa\textsubscript{O\textsubscript{2}}/Fi\textsubscript{O\textsubscript{2}} 200–300) receiving high-PEEP strategies (27.2% versus 19.4%; RR 1.37, 95% CI, 0.98–1.92; P = 0.07). The putative mechanism for the interaction between ARDS severity and the effect of PEEP on mortality is that moderate-to-severe ARDS, and its more severe edema and lung collapse, may respond favorably to higher PEEP, whereas high PEEP may result in overdistention of healthy lung in mild ARDS (Figure 2). What remains unanswered is how to select the optimal PEEP level that assists in lung recruitment without causing lung overdistention. Many approaches have been published, including use of a PEEP-and-Fi\textsubscript{O\textsubscript{2}} table, use of the inflection points of the lung pressure–volume curve, titration of PEEP to a maximal plateau pressure of 30 cm H\textsubscript{2}O, using the “stress index” of the pressure tracing during constant-flow volume-control ventilation to determine tidal hyperinflation versus derecruitment, and esophageal manometry. Thus although “higher” PEEP may be beneficial in moderate and severe ARDS, the best method to determine the optimal PEEP level for each patient is unclear and is an important area of further research.

High-frequency ventilation

High-frequency ventilation takes the concept of low tidal–volume, open-lung ventilation to an extreme, using elevated continuous airway pressure (20–40 cm H\textsubscript{2}O) and very low tidal volumes at very high frequencies (3–7 Hz) to oxygenate and ventilate lungs through convective gas motion. Potential risks of high-frequency ventilation include the need for deep sedation and paralytics, severe respiratory...
Figure 2. Differential responses to increasing levels of positive end expiratory pressure among patients with ARDS as shown by computed tomography lung images and pressure-volume curves. Total respiratory system P–V curve under zero positive end-expiratory pressure (PEEP) (ZEEP) conditions (top left), lung-density histogram analysis (top right), tomographic lung-scan cuts (bottom) under ZEEP (open squares), PEEP_1 (solid circles), and PEEP_2 (open circles) conditions of a typical case from the group of patients with (A) and without (B) a lower inflection point.

Notes: (A) A lower inflection point was noted at 10 cm H_2O, and the patient was ventilated with a PEEP_1 of 12 cm H_2O and a PEEP_2 of 17 cm H_2O. Further alveolar recruitment was observed in the linear part of the P–V curve, above the lower inflection point, without concomitant alveolar overdistension, as attested to by the absence of lung parenchyma with a computed tomography (CT) number less than –900 Hounsfield units. (B) No lower inflection point was noted, and the patient was ventilated with PEEP_1 of 10 cm H_2O and PEEP_2 of 15 cm H_2O. Alveolar recruitment occurred at the two PEEP levels with simultaneous overdistension, as attested by the increased volume of lung parenchyma with a CT number less than –900 Hounsfield units.

acidosis, and risk of progressive air trapping and barotrauma. A meta-analysis of eight randomized controlled clinical trials comparing high-frequency ventilation to conventional mechanical ventilation in patients with ARDS found that patients randomized to high-frequency ventilation had a 24% (95% CI 10%–40%, \(P < 0.001\)) improvement in \(\text{PaO}_2/\text{FiO}_2\) ratio at 24 hours and a reduced 30-day hospital mortality (RR 0.77 [95% CI 0.61–0.98], \(P = 0.03\)). However, heterogeneity was high among the clinical trials included in the analysis, as two trials were conducted on pediatric patients and the trials used multiple different high-frequency ventilation methods. Importantly, very few adult patients in the comparator groups received mechanical ventilation with the standard-of-care ARDSNet strategy. High-frequency ventilation is currently an experimental alternative to conventional ventilation that likely improves oxygenation; outcome benefits will be evaluated in the multicenter Oscillation for ARDS Treated Early (OSCILLATE) trial (NCT01506401).

**Nonmechanical ventilator adjunctive therapies**

**Prone positioning**
Repositioning from supine to prone position alleviates lung compression from mediastinal and abdominal structures, redistributes lung edema to less perfused areas (enhancing oxygenation), and potentially reduces injurious transpulmonary pressures. In addition, prone position facilitates postural lung drainage and reduces the incidence of ventilator-associated pneumonia. However, prone positioning is associated with increased risks for adverse events, such as pressure ulcers, endotracheal obstruction, and accidental catheter or tube dislodgement. The evolution of the evidence in support of prone ventilation mirrors that of high PEEP. Despite improvement in oxygenation with prone ventilation in patients with ARDS, individual multicenter trials have not shown a mortality benefit. However, a meta-analysis and systematic review of ten trials with a cumulative enrollment of 1867 ARDS patients demonstrated an improvement in mortality (RR 0.84 [95% CI 0.74–0.96], \(P = 0.01\)) with prone ventilation only in patients with severe ARDS. Since a dedicated clinical trial evaluating prone positioning in severe ARDS may not be feasible, it is reasonable to utilize this approach in patients with severe ARDS.

**Inhaled pulmonary vasodilator therapy**
Inhaled pulmonary vasodilators (eg, nitric oxide, prostacyclin) are intended to induce vasodilatation of the pulmonary vasculature in ventilated lung in order to improve pulmonary hypertension, ventilation–perfusion matching, and oxygenation. Despite the putative physiologic benefits of improved oxygenation and reduced pulmonary vascular resistance, inhaled vasodilator trials have failed to show a mortality advantage. In meta-analysis, inhaled nitric oxide showed only transient improvements in oxygenation (13% [95% CI 4%–23%] increase compared to control at 24 hours, \(P = 0.003; 4\% [95\% \text{CI 2\%–13\%}] \text{ increase at 72 hours, } P = 0.17\)). Further, results demonstrated a trend towards increased mortality (RR 1.10 [95% CI 0.94–1.30]) and a significant increase in renal dysfunction (RR 1.50 [95% CI 1.11–2.02]) in patients randomized to receive inhaled nitric oxide. Based on the lack of evidence in support of this therapy, we do not recommend inhaled vasodilator therapy for ARDS.

**Extracorporeal membrane oxygenation (ECMO)**

The process of ECMO for severe ARDS involves the rerouting of blood outside the body to external “lung” membranes that function to oxygenate and remove \(\text{CO}_2\) from the blood. ECMO assumes the main gas-exchange function in the patient with severely compromised lungs to allow “lung rest” and avoid further VALI. Initiation of ECMO involves anticoagulation and the surgical placement of one or two large-bore (21–30 Fr) catheters that pump blood through the “lung” membranes. Early ECMO trials failed to show mortality benefit in the treatment of ARDS. However, interest in ECMO has been revived by results of the randomized Conventional Ventilation or ECMO for Severe Adult Respiratory failure (CESAR) trial, which showed a reduction in the primary outcome of death or severe disability at 6 months (37% versus 53%; RR 0.69 [95% CI 0.05–0.97], \(P = 0.03\)) for patients referred for consideration of ECMO therapy. However, results of CESAR are confounded by the question of whether the benefit in the “consideration for ECMO” arm was the result of ECMO (used in only 75% of randomized patients) or due to greater use of a lung-protective ventilation strategy in the ECMO referral center. Due to the high risk of hemorrhage (54%– including intracranial hemorrhage in 9% of patients – ECMO is contraindicated in patients with conditions precluding anticoagulation. In addition, any potential benefit of ECMO likely wanes after ARDS duration of more than 7 days. However, in patients with early and severe ARDS without contraindication, transfer to a specialized center for consideration of ECMO may be a reasonable approach.

**Corticosteroid therapy**
Because inflammation is thought to be a primary driver of lung injury, there has been considerable interest in...
using anti-inflammatory medications to treat ARDS. Thus far, trials of anti-inflammatory drugs have failed to show significant benefit. The most studied anti-inflammatory medication in ARDS – corticosteroids – warrants more detailed discussion. Trials of short-burst (eg, 24–48 hours), high-dose corticosteroids (eg, methylprednisolone 30 mg/kg every 6 hours) showed that corticosteroids neither reduced ARDS incidence (OR 1.55, 95% CI 0.58–4.05) nor mortality (OR 0.75 [95% CI 0.41–1.57]). More controversy exists for low-dose corticosteroids (0.5–1 mg/kg/day methylprednisolone). ARDSNet enrolled patients with unresolved ARDS for >7 days and found no mortality advantage over placebo (29.2% versus 28.6%). Subgroup analysis showed that patients receiving methylprednisolone therapy 14 days after diagnosis of ARDS actually experienced increased mortality compared to placebo. The ARDSNet results differ from those of Meduri et al, who found decreased ICU mortality and a trend to decreased hospital mortality (24% versus 43%, P = 0.07) in patients randomized to a 28-day continuous-infusion methylprednisolone taper (from 1 mg/kg/day to 0.125 mg/kg/day). However, Meduri et al did not specify sample-size goals or stopping rules, did not utilize alpha spending for multiple interim analyses, and allowed crossover of placebo “nonresponders” to corticosteroids after 9 days. Thus, it is possible that the trial showed increased mortality from late initiation of corticosteroids in the placebo-arm group (as per results of the ARDSNet trial), rather than decreased mortality from early corticosteroids. Meta-analyses of ARDS corticosteroid trials have similarly shown a lack of significant benefit. Given the absence of convincing evidence regarding benefits, we do not routinely use corticosteroids for prevention or treatment of ARDS.

Neuromuscular blocking agents

Neuromuscular blocking medications are used to induce paralysis and decrease patient–ventilator dysynchrony. Studies investigating the potential benefit of short-term neuromuscular blocking agents in early ARDS have been promising. Papazian et al randomized 340 patients with ARDS (PaO₂/FiO₂ < 150) to a 48-hour infusion of cisatracurium versus placebo and found a significant reduction in adjusted 90-day mortality (RR 0.68 [95% CI 0.48–0.98], P = 0.04) and trend toward a reduction of the crude 90-day mortality (31.6% versus 40.7%; P = 0.08). The study did not find increased development of muscle weakness with short-term cisatracurium infusion compared to placebo. Putative benefits of neuromuscular blockade include reduction in injurious transpulmonary pressures from improved patient–ventilator synchrony and immunomodulatory properties. Short-term, early neuromuscular blockade appears to be a safe and potentially beneficial strategy for patients with severe ARDS.

Fluid management

Although ARDS is defined by the presence of “noncardiogenic” pulmonary edema, 30% of patients identified clinically as having ARDS have pulmonary artery occlusion pressures greater than 18 mmHg. Even in patients without elevated cardiac filling pressure, reducing hydrostatic forces has the potential to improve ARDS outcomes. The ARDSNet Fluid and Catheter Treatment Trial investigated the effect of fluid management and hemodynamic monitoring strategies. Although a significant difference in 60-day mortality was not achieved (conservative fluid 25.5% versus liberal fluid 28.4%, P = 0.60), patients receiving a conservative fluid approach had decreased duration of mechanical ventilation and improved lung function, without increased adverse events. Therefore, a conservative fluid approach with a goal central venous pressure of 4 mm Hg for patients with adequate urine output (>0.5 cc/kg/hour) and effective circulation may facilitate ventilator liberation in patients with ARDS.

Prevention

Because there are few beneficial treatments, recent studies have focused on identifying ways to prevent the development of ARDS. In a single-center observational study, Yilmaz et al demonstrated that the combination of a low tidal–volume and restrictive blood product–transfusion strategy in mechanically ventilated patients was associated with a reduction in ARDS incidence. Determann et al randomized at-risk patients to low tidal–volume or conventional tidal–volume strategies and showed reduced ARDS incidence (2.6% versus 13.5%; P = 0.01) and decreased inflammatory cytokines in patients given low tidal volumes. Remarkably, the use of lower tidal volumes in patients requiring mechanical ventilation may be altering the epidemiology of ARDS. In a single-center study, Li et al demonstrated that the incidence of ARDS declined markedly during the years 2001–08 (from 82.4 to 38.9 per 100,000 person-years). Notably, the decline in incidence was seen only in hospital-acquired ARDS, rather than ARDS that was present on admission. The authors hypothesized that adoption of restrictive blood transfusion and low tidal–volume ventilation practices may reduce “second hit” factors that increase risk for ARDS.
Future directions
Clinical epidemiologists have myriad opportunities to continue to enhance our understanding of ARDS. These include development of methods to reliably identify ARDS in enhanced administrative databases, determination of factors associated with the large variation in incidence of ARDS, and improved characterization of risk modifiers for ARDS development, progression, and mortality. In addition, only a minority of ARDS patients currently receive evidence-based lung-protective ventilation strategies.73–77 Studies that investigate strategies to improve implementation of low tidal–volume ventilation are a primary priority for ARDS research. Further, studies that compare effectiveness of alternative ventilator strategies (ie, airway pressure–release ventilation78 and variable ventilation)79 to the low tidal–volume standard of care are needed. However, even with perfect implementation of lung-protective ventilation, mortality is unacceptably high. Thus, studies that evaluate existing medications with potentially beneficial anti-inflammatory side effects – such as the cholesterol-lowering “statins” (NCT00979121), macrolide antibiotics80 and aspirin (NCT01504867) – may find novel treatments for ARDS. Lastly, continued identification of specific ARDS phenotypes that may benefit from certain treatment strategies (eg, high PEEP) may enhance our understanding of the pathophysiology of ARDS.

Conclusion
The past quarter-century has seen significant progress in our understanding of ARDS. The difficult task of establishing a consensus definition for a syndrome with multiple precipitants allowed for coordinated clinical study that ultimately resulted in a therapeutic approach that improves mortality. Lung-protective ventilation strategies that limit further lung injury, reduce systemic release of inflammatory mediators, and attenuate multiorgan system failure currently represent the standard of care for ARDS. However, our understanding of ARDS epidemiology contains large knowledge gaps, mortality remains unacceptably high, and additional treatments are sorely needed. Clinical epidemiologists will undoubtedly continue to play a large role in enhancing the care of patients with ARDS.

Disclosure
The authors report no conflicts of interest in this work.

References


